The NF-κB-inducing kinase (NIK), a molecule pivotal for immune system development and function, shows significant yet complex potential as a therapeutic target. The comprehensive review, published by ...

Two decades ago, Professor Shao-Cong Sun first discovered the non-canonical NF-κB pathway mediated by NF-κB-inducing kinase (NIK). Since then, more ...

Alumis (NASDAQ:ALMS) executives highlighted recent clinical progress for the company’s TYK2 inhibitor programs and previewed multiple upcoming catalysts during remarks at the Leerink Partners Global ...

Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.

In a cohort study of nearly 16,000 US patients with breast cancer who were prescribed a cyclin-dependent kinase (CDK) 4/6 inhibitor, only 46% underwent liver function testing in the 2 weeks before ...

The impact of neflamapimod on neurofilament light levels will be examined in a study of approximately 35 patients with ALS, facilitated by the EXPERTS-ALS platform, according to a press release from ...

Solid Biosciences Inc. shares dropped more than 8% on Wednesday after the company released data from its Duchenne gene therapy trial. Trading in the stock was briefly halted earlier in the day. The ...

Common supplements like melatonin and magnesium can interact with your prescription drugs. Learn which sleep aids to avoid to stay healthy.

Explore new findings on ovarian cancer and how blocking focal adhesion kinase can enhance immune response in treatment.

In 1967, Hungarian scientist Endre Mester tried to cure skin cancer in mice using a low-powered ruby laser. He failed to stop ...

Sotyktu (deucravacitinib) for treatment of adults with active psoriatic arthritis (PsA). Sotyktu is an oral, selective ...

In a March 10 update, Leede analyst Douglas Loe maintained a “Speculative Buy” rating and US$16.00 target on Satellos Bioscience ...